Profile data is unavailable for this security.
About the company
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Company’s proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
- Revenue in USD (TTM)25.47m
- Net income in USD-15.63m
- Incorporated2001
- Employees62.00
- LocationMolecular Templates Inc9301 Amberglen Blvd Ste 100AUSTIN 78729-1153United StatesUSA
- Phone+1 (512) 896-1555
- Fax+1 (302) 655-5049
- Websitehttps://mtem.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vitro Biopharma Inc | 2.11m | -10.44m | 8.05m | 10.00 | -- | -- | -- | 3.82 | -2.35 | -2.35 | 0.4745 | -1.69 | 0.2765 | 1.71 | 20.61 | 210,873.00 | -136.91 | -- | -1,046.98 | -- | 83.48 | -- | -495.08 | -- | 0.1865 | -4.19 | -- | -- | -46.45 | -- | 31.01 | -- | -- | -- |
| Nascent Biotech Inc | 0.00 | -1.92m | 8.08m | -- | -- | -- | -- | -- | -0.012 | -0.012 | 0.00 | -0.003 | 0.00 | -- | -- | -- | -1,256.81 | -708.50 | -- | -- | -- | -- | -- | -589.83 | -- | -- | -- | -- | -- | -- | 25.47 | -- | -- | -- |
| Mustang Bio Inc | 0.00 | -32.06m | 8.27m | 80.00 | -- | -- | -- | -- | -2.91 | -2.91 | 0.00 | -0.2384 | 0.00 | -- | -- | 0.00 | -170.53 | -70.02 | -727.24 | -79.98 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 33.44 | -- | -60.75 | -- |
| Silexion Therapeutics Corp | 0.00 | -523.87k | 8.50m | 0.00 | -- | 1.33 | -- | -- | -0.1403 | -0.1403 | 0.00 | 0.6559 | 0.00 | -- | -- | -- | -3.13 | -- | -3.77 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.96 | -- | -- | -- |
| Carmell Corp | 12.32k | -15.97m | 8.60m | 9.00 | -- | -- | -- | 698.09 | -1.53 | -1.44 | 0.0006 | -0.0656 | -- | -- | -- | 1,368.89 | -- | -- | -- | -- | 58.73 | -- | -129,263.60 | -- | 0.6901 | -- | -- | -- | -- | -- | -75.70 | -- | -- | -- |
| ABVC Biopharma Inc | 136.40k | -11.37m | 8.64m | 16.00 | -- | 1.01 | -- | 63.36 | -1.78 | -1.78 | 0.0172 | 0.6882 | 0.0114 | -- | 0.4213 | 8,525.00 | -99.79 | -103.38 | -197.79 | -231.54 | -24.11 | 76.25 | -8,762.13 | -2,019.89 | -- | -2.50 | 0.1873 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
| Soligenix Inc | 494.62k | -7.04m | 8.71m | 13.00 | -- | 1.70 | -- | 17.61 | -9.58 | -9.58 | 0.6152 | 2.25 | 0.0418 | -- | 8.70 | 38,047.69 | -59.45 | -75.40 | -121.64 | -154.32 | 8.75 | 22.83 | -1,423.81 | -620.02 | -- | -- | 0.4421 | -- | -11.54 | -30.67 | 55.50 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -24.92m | 8.81m | 41.00 | -- | -- | -- | -- | -5.41 | -5.41 | 0.00 | -1.82 | 0.00 | -- | -- | 0.00 | -279.89 | -- | -- | -- | -- | -- | -- | -- | -- | -27.58 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -45.34m | 8.82m | 40.00 | -- | -- | -- | -- | -1.16 | -1.16 | 0.00 | 0.0678 | 0.00 | -- | -- | 0.00 | -83.82 | -86.35 | -140.98 | -106.38 | -- | -- | -- | -11,853.94 | -- | -59.78 | 0.8753 | -- | -- | -- | -3.78 | -- | -- | -- |
| Molecular Templates Inc | 25.47m | -15.63m | 8.89m | 62.00 | -- | 1.25 | -- | 0.349 | -2.70 | -2.70 | 4.24 | 1.08 | 0.8189 | -- | 47.65 | 410,806.40 | -50.24 | -51.78 | -113.26 | -73.14 | -- | -- | -61.35 | -228.33 | -- | -- | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
| BioCardia Inc | 428.00k | -8.56m | 8.89m | 16.00 | -- | -- | -- | 20.78 | -5.40 | -5.40 | 0.2636 | -0.9233 | 0.0923 | -- | 6.85 | 26,750.00 | -184.48 | -107.34 | -1,075.25 | -154.17 | -- | -- | -1,999.77 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| Inhibikase Therapeutics Inc | 79.57k | -18.38m | 8.96m | 8.00 | -- | 1.70 | -- | 112.57 | -2.93 | -2.93 | 0.0126 | 0.7063 | 0.0051 | -- | -- | 9,946.25 | -117.93 | -66.49 | -148.63 | -85.55 | -- | -- | -23,102.16 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Portage Biotech Inc | 0.00 | -71.08m | 9.15m | 7.00 | -- | 3.64 | -- | -- | -68.81 | -68.81 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -137.29 | -30.53 | -143.21 | -40.02 | -- | -- | -- | -- | -- | -- | 0.02 | -- | -- | -- | 27.98 | -- | -- | -- |
| Kintara Therapeutics Inc | 0.00 | -9.51m | 9.63m | 2.00 | -- | -- | -- | -- | -4.08 | -4.08 | 0.00 | 0.1071 | 0.00 | -- | -- | 0.00 | -131.55 | -220.94 | -185.60 | -329.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 40.24 | -- | 78.93 | -- |
| Plus Therapeutics Inc (USA) | 5.51m | -13.23m | 9.67m | 20.00 | -- | -- | -- | 1.76 | -3.05 | -3.05 | 1.19 | -1.34 | 0.4336 | -- | -- | 275,450.00 | -104.14 | -59.18 | -- | -133.04 | -- | -- | -240.15 | -470.45 | -- | -4.17 | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| Kazia Therapeutics Ltd (ADR) | 15.35k | -13.93m | 9.67m | 12.00 | -- | 0.9028 | -- | 630.04 | -0.8448 | -0.8448 | 0.0008 | 0.3597 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Molecular Templates Inc's reporting currency: US Dollar USD
41.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bellevue Asset Management AGas of 01 Aug 2024 | 1.28m | 19.44% |
| SilverArc Capital Management LLCas of 01 Aug 2024 | 623.84k | 9.48% |
| BVF Partners LPas of 30 Jun 2024 | 522.24k | 7.93% |
| Caxton Corp.as of 30 Jun 2024 | 136.87k | 2.08% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 59.60k | 0.91% |
| Geode Capital Management LLCas of 30 Jun 2024 | 41.99k | 0.64% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 38.13k | 0.58% |
| HRT Financial LLCas of 30 Jun 2024 | 18.48k | 0.28% |
| Invst LLCas of 30 Jun 2024 | 18.00k | 0.27% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 15.17k | 0.23% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
